FDA Research Opportunity for studies involved evaluation of Human Sex-biased MicroRNAs in Coagulation ProteinsJanuary 27th, 2026 Organization U.S. Food and Drug Administration (FDA) Reference Code FDA-OWH-2026-0001 How to Apply To submit your application, scroll to the bottom of this opportunity and click APPLY. A complete application consists of:
All documents must be in English or include an official English translation. If you have questions, send an email to [email protected]. Please include the reference code for this opportunity in your email. Connect with ORISE...on the GO! Download the new ORISE GO mobile app in the Apple App Store or Google Play Store to help you stay engaged, connected, and informed during your ORISE experience and beyond! Application Deadline 5/15/2026 3:00:00 PM Eastern Time Zone Description *Applications will be reviewed on a rolling-basis. FDA Office and Location: A Postdoctoral Fellow opportunity is available with Dr. Chava Kimchi-Sarfaty and located at Hemostasis Branch 1 (HB1), Division of Hemostasis (DH), Office of Plasma Protein Therapeutics (OPPT), Office of Therapeutic Products (OTP), Center for Biologics Evaluation and Research (CBER) in Silver Spring, Maryland. Funding for this opportunity will be provided by the Office of Commissioner (OC), Office of Women's Health (OWH). Research Project: Under the guidance of the mentor, the participant will investigate sex-biased microRNAs (miRNAs) and their regulatory effects on coagulation proteins, particularly ADAMTS13 and von Willebrand Factor (VWF), to understand sex-dependent differences in bleeding disorders such as thrombotic thrombocytopenic purpura (TTP) and von Willebrand Disease (VWD). This research aims to improve FDA-regulated product quality, safety, and efficacy for women's health applications and facilitate development of sex-specific therapeutic strategies. Learning Objectives:
Mentor: The mentor for this opportunity is Dr. Chava Kimchi-Sarfaty ([email protected]). If you have questions about the nature of the research, please contact the mentor. Anticipated Appointment Start Date: 2026. Start date is flexible and will depend on a variety of factors. Appointment Length: The appointment will initially be for one year but may be renewed upon recommendation of FDA and is contingent on the availability of funds. Level of Participation: The appointment is full time. Participant Stipend: The participant will receive a monthly stipend commensurate with educational level and experience. Citizenship Requirements: This opportunity is available to U.S. citizens, Lawful Permanent Residents (LPR), and foreign nationals. Non-U.S. citizen applicants should refer to the Guidelines for Non-U.S. Citizens Details page of the program website for information about the valid immigration statuses that are acceptable for program participation. This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits. Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years. FDA Ethics Requirements If an ORISE Fellow, to include their spouse and minor children, reports what is identified as a Significantly Regulated Organization (SRO) or prohibited investment fund financial interest in any amount, or a relationship with an SRO, except for spousal employment with an SRO, and the individual will not voluntarily divest the financial interest or terminate the relationship, then the individual is not placed at FDA. For additional requirements, see FDA Ethics for Nonemployee Scientists. FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:
Qualifications The qualified candidate should have received a Ph.D. or equivalent degree with an educational background in molecular and cell biology, pharmacology and drug discovery/development, or be currently pursuing. Degree must have been received within the past five years or be currently pursuing. Lab skills in common molecular and cell biology techniques are preferred. Point of Contact Eligibility Requirements
Affirmation I am a U.S. citizen, or I have lived in the United States for at least 36 out of the past 60 months. (36 months do not have to be consecutive.)
|